Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 1:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 988 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bipolar Disorder Clear all
Completed Phase 4 Interventional Results available

Inositol and Omega-3 Fatty Acids in Pediatric Mania

NCT01396486
View directory record Official record
Conditions
Pediatric Bipolar Spectrum Disorders
Interventions
Omega-3, Inositol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 12 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Jun 7, 2026, 1:54 AM EDT
Completed Phase 3 Interventional

Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder

NCT00277654
View directory record Official record
Conditions
Bipolar Disorder, Anxiety Disorder
Interventions
Risperidone
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 12, 2011 · Synced Jun 7, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder

NCT00227305
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
31
States / cities
Dothan, Alabama • Scottsdale, Arizona • Cerritos, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Jun 7, 2026, 1:54 AM EDT
Recruiting Phase 2 Interventional

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

NCT07494305
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
LB-102, Placebo
Drug · Other
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jun 7, 2026, 1:54 AM EDT
Completed Phase 2 Interventional

8 Week Multi-site Study of MYDAYIS® for Bipolar Depression

NCT04235686
View directory record Official record
Conditions
Bipolar Depression
Interventions
Mydayis Extended-Release Capsule, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jun 7, 2026, 1:54 AM EDT
Completed Phase 3 Interventional

Study Evaluating Bifeprunox in Bipolar Depression

NCT00245973
View directory record Official record
Conditions
Depression Bipolar
Interventions
Bifeprunox
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
40
States / cities
Birmingham, Alabama • Beverly Hills, California • National City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2007 · Synced Jun 7, 2026, 1:54 AM EDT
Not listed Phase 4 Interventional

Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder

NCT00325286
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Plus Extended- Release Carbamazepine
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 13, 2007 · Synced Jun 7, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder

NCT04276883
View directory record Official record
Conditions
Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder
Interventions
Sublingual film containing Dexmedetomidine (BXCL501), Placebo Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 7, 2026, 1:54 AM EDT
Completed Phase 4 Interventional

The Effects of Aripiprazole on Patients With Metabolic Syndrome

NCT00224822
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Metabolic Syndrome X
Interventions
Aripiprazole
Drug
Lead sponsor
New Mexico VA Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Jun 7, 2026, 1:54 AM EDT
Completed Not applicable Interventional

Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis

NCT01570972
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychotic Disorder Not Otherwise Specified (NOS)
Interventions
Group Cognitive Behavioral Therapy, Multifamily Group Psychoeducation
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 35 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Jun 7, 2026, 1:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spectroscopy in Children and Adolescents With Bipolar Disorder

NCT00181831
View directory record Official record
Conditions
Bipolar Disorder, ADHD
Interventions
Proton Magnetic Resonance Spectroscopy
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Jun 7, 2026, 1:54 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

NCT06608641
View directory record Official record
Conditions
Bipolar 1 Disorder
Interventions
Endoxifen enteric-coated tablet (8 mg), Placebo Tablets
Drug
Lead sponsor
Jina Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Cerritos, California • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Jun 7, 2026, 1:54 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder

NCT03206463
View directory record Official record
Conditions
Delta-9-Tetrahydroncannabinol, Bipolar Disorder, Healthy Controls
Interventions
4 mg Delta-9-THC, Placebo, 2 mg Delta-9-THC
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Jun 7, 2026, 1:54 AM EDT
Completed Phase 2Phase 3 Interventional

NRX101 Glx Biomarker Validation Study

NCT03402152
View directory record Official record
Conditions
Bipolar Depression, Suicidal Ideation
Interventions
NRX-101, Lurasidone HCl, Placebo
Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Jun 7, 2026, 1:54 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder

NCT02527564
View directory record Official record
Conditions
Insomnia, Bipolar Disorder
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Jun 7, 2026, 1:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)

NCT01172652
View directory record Official record
Conditions
Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Palo Alto, California • Tampa, Florida • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jun 7, 2026, 1:54 AM EDT
Recruiting Phase 1 Interventional

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

NCT06305598
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Bone Scan, Computed Tomography, Leuprolide Acetate, Magnetic Resonance Imaging, Survey Administration, Testosterone Cypionate
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jun 7, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder

NCT03257865
View directory record Official record
Conditions
Bipolar I Disorder, Manic Episode
Interventions
Brexpiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Little Rock, Arkansas • Bellflower, California • Cerritos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Jun 7, 2026, 1:54 AM EDT
Suspended Phase 4 Interventional

IM Ketamine vs Midazolam for Suicidal ER Patients

NCT04640636
View directory record Official record
Conditions
Depression, Unipolar, Depression, Bipolar, Suicidal Ideation
Interventions
Ketamine hydrochloride injection, Midazolam injection
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 7, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

Staccato Loxapine in Agitated Patients With Bipolar Disorder

NCT00721955
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Inhaled Placebo, Inhaled loxapine 5 mg, Inhaled loxapine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Escondido, California • Garden Grove, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Jun 7, 2026, 1:54 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)

NCT06081426
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Non-ketogenic Diet, Ketogenic Diet, No diet
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 40 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jun 7, 2026, 1:54 AM EDT
Completed Phase 2Phase 3 Interventional

Investigating tDCS as a Treatment for Unipolar and Bipolar Depression

NCT01562184
View directory record Official record
Conditions
Unipolar Depression, Bipolar Depression
Interventions
Sham tDCS device, Soterix tDCS device
Device
Lead sponsor
The University of New South Wales
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Atlanta, Georgia • Towson, Maryland • Cherry Hill, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Jun 7, 2026, 1:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bipolar Research Study Using MR Imaging

NCT02083978
View directory record Official record
Conditions
Bipolar Affective Disorder
Interventions
MRI scanning
Other
Lead sponsor
Washington University Early Recognition Center
Other
Eligibility
18 Years to 30 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Jun 7, 2026, 1:54 AM EDT
Completed No phase listed Observational Results available

Genetic Predictors of Lithium Response in Bipolar Disorder

NCT00252577
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium treatment
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Jun 7, 2026, 1:54 AM EDT